FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Tina Woods

Research Profile

Anatomy

Disorders

Physiology

Living Beings

Chemicals & Drugs

Procedures

Echocardiography

Concepts & Ideas

Survival Rate

Co-author Network

Publications

TOP 3
Weike Bao; David J Behm; Sandhya S Nerurkar; Zhaohui Ao; Ross Bentley; Rosanna Mirabile; Douglas G Johns; Tina N Woods; Christopher P A Doe; Robert W Coatney; Jason F Ohlstein; Stephen Douglas; Robert N Willette; Tian-Li Yue
Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.
David J Behm; Stephen M Harrison; Zhaohui Ao; Kristeen Maniscalco; Susan J Pickering; Evelyn Grau; Tina N Woods; Robert W Coatney; Christopher P A Doe; Robert N Willette; Douglas G Johns; Stephen Douglas
Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.
Robert N Willette; K M Anderson; Allen H Nelson; Alan R Olzinski; Tina N Woods; Robert W Coatney; Nambi Aiyar; Eliot ohlstein; Frank C Barone
Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Tina Woods (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Weike Bao; David J Behm; Sandhya S Nerurkar; Zhaohui Ao; Ross Bentley; Rosanna Mirabile; Douglas G Johns; Tina N Woods; Christopher P A Doe; Robert W Coatney; Jason F Ohlstein; Stephen Douglas; Robert N Willette; Tian-Li Yue
Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.
Journal of cardiovascular pharmacology 2007;49(6):362-8.
2003: David J Behm; Stephen M Harrison; Zhaohui Ao; Kristeen Maniscalco; Susan J Pickering; Evelyn Grau; Tina N Woods; Robert W Coatney; Christopher P A Doe; Robert N Willette; Douglas G Johns; Stephen Douglas
Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.
British journal of pharmacology 2003;139(2):464-72.
2001: Robert N Willette; K M Anderson; Allen H Nelson; Alan R Olzinski; Tina N Woods; Robert W Coatney; Nambi Aiyar; Eliot ohlstein; Frank C Barone
Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.
Journal of cardiovascular pharmacology 2001;38(4):606-17.
2001: T M Behr; Sandhya S Nerurkar; Allen H Nelson; Robert W Coatney; Tina N Woods; Anthony C Sulpizio; Sudeep Chandra; David P Brooks; Sanjay Kumar; John Lee; Eliot ohlstein; Christiane E Angermann; Jerry L Adams; J Sisko; Jonathan D Sackner-Bernstein; Robert N Willette
Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction.
Circulation 2001;104(11):1292-8.